克拉斯
MAPK/ERK通路
曲美替尼
MEK抑制剂
神经母细胞瘤RAS病毒癌基因同源物
组织细胞
组织细胞肉瘤
癌症研究
肿瘤科
医学
激酶
内科学
生物
病理
遗传学
癌症
结直肠癌
作者
Eli L. Diamond,Benjamin Heath Durham,Gary A. Ulaner,Esther N Drill,Justin J. Buthorn,Michelle Ki,Lillian E Bitner,Hanna Cho,Robert J. Young,Jasmine H. Francis,Raajit K. Rampal,Mario E. Lacouture,Lynn A. Brody,Neval Özkaya,Ahmet Doǧan,Neal X. Rosen,Alexia E. Iasonos,Omar Ibrahim Abdel-Wahab,David Michael Hyman
出处
期刊:Nature
[Nature Portfolio]
日期:2019-03-13
卷期号:567 (7749): 521-524
被引量:437
标识
DOI:10.1038/s41586-019-1012-y
摘要
Histiocytic neoplasms are a heterogeneous group of clonal haematopoietic disorders that are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway1,2. For the 50% of patients with histiocytosis who have BRAFV600 mutations3–5, RAF inhibition is highly efficacious and has markedly altered the natural history of the disease6,7. However, no standard therapy exists for the remaining 50% of patients who lack BRAFV600 mutations. Although ERK dependence has been hypothesized to be a consistent feature across histiocytic neoplasms, this remains clinically unproven and many of the kinase mutations that are found in patients who lack BRAFV600 mutations have not previously been biologically characterized. Here we show ERK dependency in histiocytoses through a proof-of-concept clinical trial of cobimetinib, an oral inhibitor of MEK1 and MEK2, in patients with histiocytoses. Patients were enrolled regardless of their tumour genotype. In parallel, MAPK alterations that were identified in treated patients were characterized for their ability to activate ERK. In the 18 patients that we treated, the overall response rate was 89% (90% confidence interval of 73–100). Responses were durable, with no acquired resistance to date. At one year, 100% of responses were ongoing and 94% of patients remained progression-free. Cobimetinib treatment was efficacious regardless of genotype, and responses were observed in patients with ARAF, BRAF, RAF1, NRAS, KRAS, MEK1 (also known as MAP2K1) and MEK2 (also known as MAP2K2) mutations. Consistent with the observed responses, the characterization of the mutations that we identified in these patients confirmed that the MAPK-pathway mutations were activating. Collectively, these data demonstrate that histiocytic neoplasms are characterized by a notable dependence on MAPK signalling—and that they are consequently responsive to MEK inhibition. These results extend the benefits of molecularly targeted therapy to the entire spectrum of patients with histiocytosis. A proof-of-concept clinical trial of patients with histiocytoses with MAPK-pathway mutations showed durable responses to treatment with the MEK1 and MEK2 inhibitor cobimetinib, which indicates that histiocytic neoplasms are dependent on MAPK signalling.
科研通智能强力驱动
Strongly Powered by AbleSci AI